BofA analyst Allen Lutz lowered the firm’s price target on GoodRx (GDRX) to $2.60 from $3 and keeps an Underperform rating on the shares. Heading into 2026, the firm maintains its positive view on the drug distributor group and updates its price targets to reflect peer group multiple changes.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX: